A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with depression and suicidal thoughts- especially when anti-depressants and talk ...

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

That's still possible but no longer required.) For treatment-resistant depression, patients usually get the esketamine nasal spray twice a week for one to four weeks. Then they take it once a week ...

However, they may cover the FDA-approved nasal spray, Spravato, which contains a derivative of ketamine called esketamine. This article examines Medicare coverage for ketamine infusion ...

Esketamine, a molecular relative of regular ... the new FDA approval means that patients will be able use the ketamine-derived nasal spray, which is marketed under the brand name Spravato, without ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment ... communities about the difference between esketamine versus ketamine, and whether esketamine ...